Revvity earnings and dividend set the backdrop for RVTY stock

Revvity (RVTY) has been in focus after releasing second quarter 2026 results alongside a fresh dividend declaration, giving investors an updated view of both current profitability and planned capital returns.

Revvity shares have climbed recently, with a 90 day share price return of 16.84% and a 1 year total shareholder return of 35.60%, while the 5 year total shareholder return remains down 36.40%. This points to improving momentum from a weaker longer term base as earnings, outlook upgrades, and product launches such as SuperFlex shape expectations around both growth and risk.

If Revvity’s earnings update has you thinking about where else growth and re rating potential might emerge, it can be useful to scan AI driven healthcare plays through the 43 healthcare AI stocks

Bulls point to Revvity’s outlook raise and AI linked backlog, while bears see modest headline earnings and a mixed multi year return record. Which side does the current valuation actually support?

Most Popular Narrative: 4.2% Undervalued

Revvity closed at $116.02 compared with a most followed fair value estimate of $121.07, which frames the current debate around what is already priced in.

Ongoing shift in product mix toward higher-margin, software-enabled and consumables-driven offerings (e.g., SaaS Signals, reagents, new IDS i20 platform), along with structural cost actions, are expected to materially expand operating and net margins, with 2026 set to start at a higher 28% operating margin baseline.

Want to see what sits behind that margin reset story? The narrative leans heavily on earnings growth, a richer software mix, and a very specific profit multiple. The key question is how those moving parts connect to that $121 fair value target.

Result: Fair Value of $121.07 (UNDERVALUED)

However, Revvity’s story can change quickly if pressure on China diagnostics volumes or weaker academic and government funding weighs more heavily on revenue and margins.

Another View on Revvity’s Valuation

While the narrative fair value of $121.07 suggests Revvity is modestly undervalued, the current P/E of 54.5x tells a different story. It sits above the Global Life Sciences average of 37x and the fair ratio of 27.5x, which points to a rich price that could compress if expectations cool. Which signal do you put more weight on as you evaluate the relationship between risk and potential reward?

Next Steps

With sentiment split between an upbeat fair value narrative and a rich P/E signal, it makes sense to check the full risk reward balance yourself. To see how both concerns and positives stack up in one place, review the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Revvity?

If Revvity has sharpened your focus, do not stop there. Use targeted stock lists to spot fresh ideas that match your risk comfort and return goals.

• Zero in on potential mispricings by reviewing companies highlighted in the 51 high quality undervalued stocks before other investors catch on.
• Strengthen your income approach by checking out the 9 dividend fortresses that can complement growth focused holdings.
• Prioritise resilience by scanning the 83 resilient stocks with low risk scores that may help balance out the bolder parts of your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.